Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary
Vivos Therapeutics, Inc. reported its first-quarter 2026 financial results, with revenue increasing by 70% year-over-year to $5.14 million. Despite the revenue growth, the company's net loss attributable to stockholders widened to $(7.68) million, and diluted loss per share increased to $(0.52). The revenue growth was primarily driven by sleep testing services and treatments from the recently acquired SCN network, with the company shifting its sales model towards medical providers and expanding its service offerings.
How this was made
The 30-second read
Why it matters
The earnings report indicates growth but also profitability concerns, influencing investor sentiment and stock performance.
Market read
The company's financial performance directly impacts its stock and sector sentiment, with potential ripple effects on related healthcare stocks.
What to watch
Potential upcoming catalysts include new product launches or strategic partnerships that could offset current losses.
Background
Vivos Therapeutics specializes in sleep apnea treatments, recently expanding through acquisitions and shifting sales strategies.
Ticker impact
The news is directly related to Vivos Therapeutics, Inc. (VVOS), providing recent financial results and operational updates.
Potential short-term decline due to widened losses and bearish sentiment, but long-term prospects depend on cost management and operational efficiency.
The revenue growth is positive, but widening losses and bearish sentiment suggest caution. The stock's recent performance and financials indicate potential volatility.
Market effects
The report highlights challenges in the medical device and sleep therapy sectors, possibly affecting sector sentiment.
Limited regional impact; primarily affecting US-based companies.
Low; the news is company-specific.
Counterpoint
The widening losses may be a temporary setback; if revenue growth accelerates and cost controls improve, the stock could rebound.
Key entities
- CompanyVivos Therapeutics, Inc.
A medical device company focused on sleep apnea solutions.
